AST/GOT1 expression status in primary resection specimen as a prognostic biomarker in human pancreatic ductal adenocarcinoma (PDAC).

e15245 Background: A novel metabolic link in PDAC has recently been established whereby the mutated KRAS molecule acts as a modulator of the cancer cell’s redox maintenance system via an increase in the Glutamic-Oxalacetic Transaminase 1 (GOT1) expression. The clinical relevance of the metabolic KRAS-GOT link is unknown in primary human patient samples. Here we studied whether the GOT1 expression status (a) correlates with the KRAS mutation status, (b) can be identified via specific clinicopathological phenotypes, and (c) has prognostic relevance. Methods: We analyzed two independent PDAC cohorts: 1. ‘International Cancer Genome Consortium’; (ICGC, 57 patients with whole-exome sequencing, genome wide expression profile, clinicopathological data, follow up) and 2. ‘Ulm’ (122 patients with molecular genetic workup, tissue-microarray, clinicopathological data, follow up). GOT1-overexpression was assessed via RNA level (ICGC) and immunohistochemistry (Ulm). Results: (a) In both cohorts the GOT1 expression sta...